MARKET

ZNTL

ZNTL

Zentalis Pharmaceuticals, Inc.
NASDAQ
1.360
0.000
0.00%
After Hours: 1.380 +0.02 +1.47% 19:30 11/20 EST
OPEN
1.330
PREV CLOSE
1.360
HIGH
1.500
LOW
1.330
VOLUME
1.46M
TURNOVER
--
52 WEEK HIGH
6.95
52 WEEK LOW
1.280
MARKET CAP
134.62M
P/E (TTM)
-0.7106
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ZNTL last week (1109-1113)?
Weekly Report · 6d ago
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Olema Pharmaceuticals (OLMA) and Zentalis Pharmaceuticals (ZNTL)
TipRanks · 11/11 10:40
Zentalis upgraded to Outperform from Neutral at Wedbush
TipRanks · 11/10 16:59
Wedbush upgrades Zentalis to Outperform with DENALI in view
TipRanks · 11/10 16:52
Wedbush Upgrades Zentalis Pharmaceuticals to Outperform, Raises Price Target to $6
Benzinga · 11/10 15:13
Zentalis Pharmaceuticals Price Target Raised to $6.00/Share From $5.00 by Wedbush
Dow Jones · 11/10 14:56
Zentalis Pharmaceuticals Raised to Outperform From Neutral by Wedbush
Dow Jones · 11/10 14:56
Morgan Stanley Remains a Hold on Zentalis Pharmaceuticals (ZNTL)
TipRanks · 11/10 13:16
More
About ZNTL
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.

Webull offers Zentalis Pharmaceuticals Inc stock information, including NASDAQ: ZNTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZNTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZNTL stock methods without spending real money on the virtual paper trading platform.